Maggie Chen

The company’s lead drug candidate, Repotrectinib, is currently in Phase I/II clinical studies to target non-small cell lung cancer (NSCLC) in patients with a ROS1 or NTRK metastatic mutation.
Part of the difficulty of treating breast cancer is the genomic variability of the patient population, as well as the different forms the cancer can take.
At the University of Southern California, Dr. Eun Ji Chung and Dr. Mitchell Gross are tackling cancer at the nanoscale.
By using naturally-derived scaffolds, human cells and other biocompatible materials, 3D bioprinting has ushered in opportunities for researchers to design, print and optimize patient personalized tissues for purposes ranging from transplantation to drug testing.